Oral acetyl-l-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study | Zendy

Michele Malaguarnera | Zendy; Marco Vacante | Zendy; Maria Giordano | Zendy; Giovanni Pennisi | Zendy; Rita Bella | Zendy; Liborio Rampello | Zendy; Mariano Malaguarnera | Zendy; Giovanni Li Volti | Zendy; Fabio Galvano | Zendy

Open Access

Oral acetyl-l-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study

Author(s) -

Michele Malaguarnera,

Marco Vacante,

Maria Giordano,

Giovanni Pennisi,

Rita Bella,

Liborio Rampello,

Mariano Malaguarnera,

Giovanni Li Volti,

Fabio Galvano

Publication year - 2011

Publication title -

american journal of clinical nutrition

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.608

H-Index - 336

eISSN - 1938-3207

pISSN - 0002-9165

DOI - 10.3945/ajcn.110.007393

Subject(s) - medicine , placebo , hepatic encephalopathy , gastroenterology , encephalopathy , pathology , cirrhosis , alternative medicine

Fatigue is frequently reported in hepatic encephalopathy (HE) and may be related to hyperammonemia. Acetyl-L-carnitine (ALC) offers neuroprotective benefits and improves mitochondrial energetics and function.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog